Cullinan To Present Results from REZILIENT1, Phase 1/2 Trial Of Zipalertinib In Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, At ASCO 2025

Author: Benzinga Newsdesk | April 23, 2025 10:16am

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (ex20ins) who have received prior therapy will be presented in an oral abstract session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 30–June 3, 2025. The data will include results from the Phase 2b portion of the study, which explored zipalertinib monotherapy in patients with advanced or metastatic EGFR ex20ins NSCLC who progressed after prior treatment with platinum-based chemotherapy with or without amivantamab and other ex20ins-targeted therapies.

Posted In: CGEM